Managing Myeloproliferative Neoplasms
Managing Myeloproliferative Neoplasms

A Case-Based Approach

Edited by

Ruben A. Mesa, MD
Consultant Hematologist and Chair, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA

Claire N. Harrison, MD
Consultant Haematologist and Deputy Clinical Director, Cancer and Haematology, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK
## Contents

*List of contributors*  vii  
*Preface*  ix  

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes</td>
<td>9</td>
</tr>
<tr>
<td>3</td>
<td>Incidental splenomegaly: an approach to diagnosis</td>
<td>17</td>
</tr>
<tr>
<td>4</td>
<td>When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm</td>
<td>22</td>
</tr>
<tr>
<td>5</td>
<td>Accurately assessing risk in your myeloproliferative neoplasm patient</td>
<td>37</td>
</tr>
<tr>
<td>6</td>
<td>Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms</td>
<td>45</td>
</tr>
<tr>
<td>7</td>
<td>The newly diagnosed patient with essential thrombocythemia</td>
<td>56</td>
</tr>
<tr>
<td>8</td>
<td>The newly diagnosed patient with polycythemia vera</td>
<td>64</td>
</tr>
<tr>
<td>9</td>
<td>Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals</td>
<td>70</td>
</tr>
<tr>
<td>10</td>
<td>Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment</td>
<td>79</td>
</tr>
<tr>
<td>11</td>
<td>Hematopoietic cell transplantation for myelofibrosis: who and when?</td>
<td>86</td>
</tr>
<tr>
<td>12</td>
<td>Systemic mast cell disease: diagnosis and management</td>
<td>97</td>
</tr>
<tr>
<td>13</td>
<td>Hypereosinophilia: an illustrated approach to diagnosis and management</td>
<td>108</td>
</tr>
<tr>
<td>14</td>
<td>Myelodysplastic/myeloproliferative neoplasm overlap syndromes</td>
<td>120</td>
</tr>
<tr>
<td>15</td>
<td>Atypical chronic myeloid leukemia and chronic neutrophilic leukemia</td>
<td>129</td>
</tr>
<tr>
<td>16</td>
<td>Women and children with myeloproliferative neoplasms – special considerations</td>
<td>137</td>
</tr>
<tr>
<td>17</td>
<td>Conception and pregnancy in myeloproliferative neoplasms</td>
<td>152</td>
</tr>
<tr>
<td>18</td>
<td>Managing acute vascular events in patients with myeloproliferative neoplasms</td>
<td>160</td>
</tr>
<tr>
<td>19</td>
<td>Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others</td>
<td>172</td>
</tr>
</tbody>
</table>
## Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Familial myeloproliferative neoplasms – implications for patients and their families</td>
<td>Sabina Swierczek and Josef Prchal</td>
<td>178</td>
</tr>
<tr>
<td>21</td>
<td>Management of acute leukemia following myeloproliferative neoplasms</td>
<td>Raoul Tibes</td>
<td>184</td>
</tr>
</tbody>
</table>

*Index* 191
Contributors

Francisco Cervantes  
Departments of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain

Nicholas C.P. Cross  
Wessex Regional Genetics Laboratory, Salisbury, and Faculty of Medicine, University of Southampton, Southampton, UK

Lorenzo Falchi  
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Veena Fauble  
Mayo Clinic, Scottsdale, AZ, USA

Guido Finazzi  
Department of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy

David A. Garcia  
Professor of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA

Holly L. Geyer  
Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA

Aaron T. Gerds  
Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA

Jason Gotlib  
Associate Professor of Medicine (Hematology), Stanford University School of Medicine/ Stanford Cancer Institute, Stanford, CA, USA

Paola Guglielmelli  
Laboratorio Congiunto Malattie Mieloproliferative Croniche, Department of Experimental and Clinical Medicine, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy

Vikas Gupta  
Princess Margaret Cancer Center, Toronto, Canada

Claire N. Harrison  
Consultant Haematologist and Deputy Clinical Director, Cancer and Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK

Dimitra Koumaki  
2nd Department of Dermatology and Venereology, Attikon University Hospital, Athens, Greece

Hans Michael Kvasnicka  
Senckenberg Institute of Pathology, University of Frankfurt, Frankfurt, Germany

Mary Frances McMullin  
Professor of Clinical Haematology, Department of Haematology, Belfast City Hospital, Queen's University Belfast, Belfast, N. Ireland

Ruben A. Mesa  
Consultant Hematologist and Chair, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA

Georgia Metzgeroth  
Department of Haematology and Oncology, University Medical Centre, Mannheim, Germany

Laura C. Michaelis  
Associate Professor, Hematology and Oncology, Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, WI, USA

Loula Papageorgiou  
Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens, Greece
List of contributors

Arturo Pereira
Department of Hemotherapy and Hemostasis, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain

Daniel A. Pollyea
Clinical Director of Leukemia Services, University of Colorado School of Medicine, Assistant Professor of Medicine, Department of Medicine, Division of Hematology, Aurora, CO, USA

Josef Prchal
Hematology, University of Utah School of Medicine, Salt Lake City, UT, USA

Deepthi Radia
Hematology Consultant, Guys and St Thomas’ NHS Foundation Trust, Haematology Department, London, UK

Craig B. Reeder
Mayo Clinic, Scottsdale, AZ, USA

Andreas Reiter
Department of Haematology and Oncology, University Medical Centre, Mannheim, Germany

Susan Robinson
Guy’s Hospital, London, UK

Bethany T. Samuelson
Hematology–Oncology, University of Washington, San Francisco, CA, USA

Robyn M. Scherber
Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA

Robert Schneidewend
Department of Oncology, Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, WI, USA

Jeffrey T. Schowinsky
University of Colorado School of Medicine, Department of Pathology, Aurora, CO, USA

Mikkael A. Sekeres
Leukemia Program, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA

Brady L. Stein
Assistant Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Sabina Swierczek
Hematology, University of Utah School of Medicine, Salt Lake City, UT, USA

Raoul Tibes
Mayo Clinic, Scottsdale, AZ, USA

Ramon V. Tiu
Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Eli-Lilly and Company, Indianapolis, IN, USA

Alessandro M. Vannucchi
Laboratorio Congiunto Malattie Mieloproliferative Croniche, Department of Experimental and Clinical Medicine, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy

Srdan Verstovsek
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Clinical manifestations of the myeloproliferative neoplasms span the breadth of hematology. The diagnostic net particularly for entities such as eosinophilia must be cast wide and can be challenging. Patients may suffer aggressive neoplastic transformation, and also hemorrhage, or thrombosis. In this book our authors, all experts in this field, will guide the reader through the entire clinical path from diagnosis to management, navigating the many changes and advances in the past decade since the description of the JAK2 V617F mutation using an engaging case-based approach.

Using clinical examples, our readers will gain an understanding of the many molecular advances (such as calreticulin and CSF3R mutations) and application of novel therapies, in particular JAK and other tyrosine kinase inhibitors.

Whatever your prior experience of this field as a trainee, consultant, pharmacist, nurse, or expert patient, this book will demystify these rare conditions and leave you confident in managing the myeloproliferative neoplasms.